Skip to main content
RNA
NASDAQ Life Sciences

Avidity Biosciences Sets February 12 Record Date for Spin-Off Ahead of Novartis Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$72.74
Mkt Cap
$10.966B
52W Low
$21.51
52W High
$72.76
52W Position info
238% above low
Off High info
at 52W high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

RNA has more than doubled off its 52-week low of $21.51.

Summary

Avidity Biosciences announced the expected record date of February 12, 2026, for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares to its stockholders, a key step in its proposed acquisition by Novartis AG.


Key Events · M&A and Partnerships · RNA

  • Spin-Off Record Date Set

    Avidity Biosciences has designated February 12, 2026, as the record date for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares.

  • Spin-Off Distribution Ratio

    Stockholders will receive one share of SpinCo common stock for every ten shares of Avidity common stock held on the record date.

  • Part of Novartis Acquisition

    This spin-off is a component of the previously announced proposed acquisition of Avidity Biosciences by Novartis AG.

  • Transaction Progress

    The announcement of the record date signifies a material step forward in the execution of the merger and spin-off, following the definitive proxy statement filed on January 30, 2026.


Analysis · RNA · Life Sciences

This filing provides a key operational update regarding the previously announced acquisition by Novartis AG and the concurrent spin-off of Atrium Therapeutics, Inc. (SpinCo). The designation of a record date for the spin-off is a concrete step towards the completion of these significant corporate transactions, indicating progress in the deal's execution. Investors should note the 1-for-10 share distribution ratio for SpinCo common stock. The overall transaction, including the spin-off, remains subject to shareholder approval and other closing conditions.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RNA was trading at $72.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $21.51 to $72.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RNA - Latest Insights

RNA
Nov 12, 2026, 4:10 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.56
Real-time Price: $7.51 info
Change: -$0.050 (-0.66%) info
Market Cap: $162.002M info
RNA
Oct 20, 2026, 8:09 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.72
Real-time Price: $7.51 info
Change: -$0.210 (-3%) info
Market Cap: $162.002M info
RNA
Oct 08, 2026, 6:52 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $7.51 info
Change: -$0.420 (-5%) info
Market Cap: $162.002M info
RNA
Oct 08, 2026, 6:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $7.51 info
Change: -$0.420 (-5%) info
Market Cap: $162.002M info
RNA
Jul 14, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $12.22
Real-time Price: $7.51 info
Change: -$4.71 (-39%) info
Market Cap: $162.002M info